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Chapter 1 
General introduction 
 
1.1. Autophagy and its molecular mechanisms 
Macroautophagy (hereafter, autophagy) is an evolutionarily conserved and self-
consumption process that degrades cellular organelles and proteins and maintains cellular 
biosynthesis during nutrient deprivation or metabolic stress [1–4]. Accumulating evidence has 
indicated the importance of autophagy in various human diseases [2–4]. The steps in autophagy 
are initiation, phagophore elongation, autophagosome formation and maturation, 
autophagosome fusion with the lysosome, and proteolytic degradation of the contents (Fig. 1.1) 
[1–4]. The products of degradation are recycled back into the cytosol and are reused to enhance 
cell survival during nutrient deprivation. In response to starvation, autophagy provides a 
nutrient source, promoting cell survival; however, autophagy is also induced by a broad range 
of other stressors and can degrade protein substrates, oxidized lipids, and damaged organelles 
[1–5]. 
The entire autophagy process is complex and involves many critical proteins. Among these, 
microtubule-associated protein light chain 3 (LC3) and sequestosome 1/p62 (p62) are 
responsible for autophagy’s membranes remodeling and trafficking events (Fig. 1.1) [6–12]. 
LC3 is an autophagosome membrane-bound protein that was first found in mammals [6]. 
Although there are several proteins that bind to the phagophore and autophagosome membranes, 
LC3 is widely used as a standard marker for these membranes because its binding is particularly 
stable [6]. After LC3 is synthesized as proLC3, it is immediately cleaved by cysteine protease 
to form LC3-I. Covalent binding of phosphatidylethanolamine to LC3-I results in LC3-II, 
which localizes to the phagophore and autophagosome membranes. The amount of LC3-II is 
1
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proportional to the number of autophagosomes present within the cell [6,7]. The protein p62 is 
a multifunctional signaling molecule involved in a variety of cellular pathways [8–12] that 
contains an ubiquitin-associated (UBA) domain for binding to ubiquitinated proteins. The 
presence of the UBA domain enables p62 to serve as an adaptor for selective autophagy of 
ubiquitinated substrates [8]. In addition, p62 itself can translocate not only to the phagophore 
membrane but also to the autophagosome formation site, even doing so independently of LC3 
binding [12]. Therefore, p62 is a critical autophagic substrate and is widely used as an indicator 
of autophagic degradation [13]. Moreover, beclin-1 is also one of the most important proteins 
for autophagy. While beclin-1 is generally ubiquitously expressed, it can also stimulate 
autophagy when overexpressed in mammalian cells [14]. It is known that beclin-1 is directly 
phosphorylated by AMP-activated protein kinase (AMPK) to induce autophagy [15]. Thus, an 
increase in the expression levels of p-beclin 1 indicates induction of autophagy. 
The number of autophagosomes is known as an indicator of the level of autophagic activity. 
However, only the assessment of autophagosome numbers is not enough to monitor reliable 
autophagy steps because that the autophagosome is an intermediate structure in the dynamic 
process of autophagy. The analysis of the degradation of autophagic substrates inside the 
lysosome, which is a phenomenon of final step of autophagy, is a more reliable indicator of 
autophagy. Most studies of the autophagy process have examined the effects of 
inducers/inhibitors on autophagy-related proteins by immunoblotting analysis, and then 
observed these proteins by microscopic analysis. 
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Figure 1.1. Schematic diagram to illustrate the process of autophagy and in the role of 
LC3-II, p62, and beclin-1. Protein substrates (a portion of cytoplasm, including organelles) 
are enclosed by a phagophore or isolation membrane to form an autophagosome. The outer 
membrane of the autophagosome subsequently fuses with the lysosome, and the internal 
material is degraded in the autolysosome. LC3-II is present both inside and outside of the 
autophagosome membrane, and the amount of LC3-II is proportional to the number of 
autophagosomes present in the cell. On the other hand, p62 is localized only inside the 
autophagosome in the autophagy process, thus the amount of p62 is widely used as an indicator 
of autophagic degradation. While beclin-1 is generally ubiquitously expressed, which can also 
stimulate autophagy when overexpressed. Beclin-1 is directly phosphorylated by AMPK to 
induce autophagy. 
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1.2. Relationship between autophagy and cancer 
In contrast to normal cells in tissues, tumors often locate within an environment deprived 
of nutrients, growth factors, and oxygen as a result of insufficient or abnormal vascularization. 
Thus, autophagy is important for supporting tumor growth (Fig. 1.2) [16–19]. In cancers, both 
the upregulation and downregulation of autophagy have been observed, which indicates its dual 
oncogenic and tumor-suppressing properties during malignant transformation [18, 19]. Liver 
cancer is the second leading cause of cancer-related death and the sixth most diagnosed cancer 
worldwide [20]. Autophagy plays multiple roles in maintaining liver homeostasis. In the 
absence of autophagy-related genes -5 and -7, which are key genes involved in autophagy 
initiation, nonfunctional proteins and organelles accumulate in liver cells [21]. It has been 
reported that autophagy-related gene 7-conditional knockout mice developed hepatomegaly and 
different metabolic liver disorders [22]; therefore, autophagy is important for suppressing 
tumorigenesis in the liver. It has been reported that in advanced hepatocellular carcinomas, 
autophagy plays an oncogenic (pro-survival) role observed as an increased LC3-II expression 
levels that positively correlates with progression of malignancy and a poor prognosis [23]. 
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The role of autophagy in cancer is complex because it depends on tumor type, stage, and 
genetic context. In addition, autophagy acts potently to either promote or inhibit tumorigenesis, 
leading to a complex picture of the relationship between autophagy and cell proliferation [24]. 
To implement an attractive tool for cancer therapy, further studies to elucidate the role of 
autophagy in cancer will be required. However, at present, there have been few reports of 
compounds with modulation of autophagy. Therefore, it would be desirable if more such 
compounds could be discovered. 
  
Figure 1.2. High metabolic demand of cancer cell and activation of autophagy. Tumor 
cells are exposed to metabolic stress due to their high metabolic demand. To respond those, 
several tumor cells activate their own autophagy to produce the amino acids for the energy 
production.  
5
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1.3. Autophagy modulators 
For medical purposes, it is valuable to identify compounds that induction or inhibition of 
autophagy [1-5, 13, 16-19, 23–28]. Autophagy inducers may have specific value in certain 
neurodegenerative diseases, some infectious diseases, and cytoprotection [1-5, 27]. The most 
potent known physiological inducer of autophagy is starvation (amino acid withdrawal), which 
induces autophagy within 1 h after starvation in most cell lines [13]. The mammalian target of 
rapamycin (mTOR) is known as a potent suppressor of autophagy [13]. Drugs or signals that 
modulate autophagy can be divided into two categories, depending on whether they act via 
mTOR or not [13, 27]. Rapamycin and its analogs CCI-779, which are mTOR inhibitors, and 
torin 1, which is an ATP-competitive inhibitor of mTOR, are well-known as mTOR-dependent 
autophagy inducers [13, 27]. On the other hand, several compounds have been reported to 
induce autophagy without the involvement of mTOR. Lithium and carbamazepine induce 
autophagy through inhibition of inositol and inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) levels 
[13, 27, 28]. It is also reported that trehalose induces autophagy by inhibition of solute carrier 
2A (SLC2A) and activation of 5' adenosine monophosphate-activated protein kinase [13, 19, 
27]. Metformin, a widely used antidiabetic agent, activates AMPK and induces autophagy [19, 
27, 28]. It is notable that neither mTOR-independent nor mTOR-dependent inhibitors are 
specific inducers of autophagy. In addition to autophagy activation, these compounds affect a 
wide range of cellular responses, particularly protein synthesis and cellular metabolism [13, 25]. 
For example, lithium attenuates autophagy through glycogen synthase kinase-3β inhibition 
(which is mTOR-dependent); therefore, if used to activate autophagy, lithium should always be 
combined with mTOR inhibitors [13]. 
On the other hand, it has been suggested that autophagy inhibition may be valuable in 
cancers [1-5, 13, 16-19, 21-28]. In addition, preclinical evidence has demonstrated the 
effectiveness of inhibiting autophagy to enhance chemotherapy-induced cytotoxicity [19, 25-
6
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27]. Autophagy inhibitors can be divided according to whether inhibition occurs before or after 
autophagosome formation. In general, inhibition of autophagosome formation is recognized as 
early-stage inhibition, and inhibition of the degradation step after autophagosome formation is 
recognized as late-stage inhibition [24, 27, 28]. Because autophagosome formation requires 
class III phosphatidylinositol 3-kinase (PI3K) activity, inhibitors of PI3K, such as 3-
methyladenine (3-MA), wortmannin, and LY294002, inhibit autophagy at an early-stage [13, 
19, 28]. On the other hand, chloroquine (CQ), hydroxychloroquine (HCQ), bafilomycin A1, 
ammonium chloride, and Lys05 are known as suppressors at the late-stage of autophagy [13, 
19, 24-28]. The use of CQ and HCQ is one of the most commonly used pharmacological 
approaches to inhibit autophagy in vitro and vivo [18, 19, 24-28]. HCQ is the preferred analog 
of CQ because of its enhanced potency and limited side effects when compared with CQ [29]. 
In addition, HCQ is one of the leading compound for anticancer drug development by 
modulating an autophagy [26]. CQ and HCQ are lysosomotropic agents with an extensive range 
of biological effects. CQ and HCQ accumulate in acidic lysosomes and increase the pH. 
Alteration of pH causes the inhibition of lysosomal hydrolases and the prevention of 
autophagosomal fusion and degradation, which can result in the inhibition of the autophagy 
process [18, 19, 25, 26, 29]. A large number of current clinical trials using HCQ indicates the 
enormous relevance of combinatory treatments with autophagy inhibition to overcome 
resistance to existing cancer therapies (Table 1.1) [19, 25, 26]. Moreover, although 3-MA is an 
early-stage inhibitor, the concentration is very high to inhibit autophagy process [13]. Therefore, 
it would be beneficial if a greater number of potent inhibitors affecting the early-stage of 
autophagy could be discovered. 
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 Chapter One 
1.4. Natural products modulating autophagy 
Recent studies have shown that natural products have beneficial effects on cancer therapy 
through autophagy [30–34]. Most of this research has reported that natural products induce 
autophagy in cancer cells. Berberine (BBR) (Fig. 1.3), an isoquinoline alkaloid isolated from 
Coptis chinensis, induces autophagic cell death by inhibiting the mTOR complex 1 through 
AMPK activation in human hepatocellular carcinoma HepG2 cells [30]. BBR was also reported 
to induce autophagic cell death by enhancing glucose-regulated protein 78 levels in HepG2 
cells and human colon carcinoma HCT-116 and DLD1 cells [31]. 
 
 
 
 
 
 
 
Zanthoxylum fruit extracts from the Japanese pepper plant Zanthoxylum piperitum 
enhance autophagic cell death through the phosphorylation of c-Jun N-terminal kinase in DLD1 
cells [32]. On the other hand, it has recently been indicated that natural products also have 
beneficial effects on cancer therapy by inhibition of autophagy. RA-XII, a natural cyclopeptide 
isolated from Rubia yunnanensis, suppresses protective autophagy to enhance apoptosis 
through AMPK/mTOR/70 kDa ribosomal protein S6 kinase pathways in HepG2 cells [33]. 
Figure 1.3. Chemical structures of BBR. 
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Moreover, phyllanthusmins, which are isolated from various Phyllanthus species, inhibit late-
stage autophagy by reducing lysosomal acidification, similar to the effects of bafilomycin A1 
inhibiting autophagy at late-stage, and followed by apoptotic cell death in high-grade serous 
ovarian cancer (OVCAR3 and OVCAR8) cells [34]. These demonstrate the importance of 
identifying the modulators from natural products to intensify cancer therapy strategies that 
modulating autophagy. 
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1.5. Purpose of this thesis 
The purpose of this thesis is to discover natural products that suppress cancer cell 
proliferation and autophagy modulation by screening our crude extract library based on 
traditional medicine and analyzing the molecular mechanisms of the products identified. This 
thesis is divided into four experimental chapters. First, in Chapter 2, we screened crude drug 
extracts to identify the extracts that modulated autophagy and cell proliferation in HepG2 cells. 
Subsequently, we demonstrated that the four extracts identified through screening showed 
inhibition of autophagy with high levels of antiproliferative activity. In Chapters 3, 4, and 5, we 
identified the active compounds that modulating autophagy in the four extracts and clarified 
their molecular mechanisms. 
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Chapter 2 
Screening of extracts prepared from crude drugs for autophagy-
mediated cell survival of the human hepatocellular carcinoma cell 
line HepG2 
 
2.1. Introduction 
In Chapter 2, we screened 130 extracts prepared from different crude drugs in a 
comprehensive search for crude drugs able to modulate autophagy. Our laboratory has a crude 
drug extract (hereafter, crude extract) library containing these 130 different crude drugs (Table 
2.1). These crude drugs are based on traditional medicines, including Japanese Kampo 
medicines. Although several biological activities of the crude drugs used in Kampo medicine 
have been evaluated, few studies have investigated their effects on autophagy. 
Human hepatocellular carcinoma cell lines (HCC) such as HepG2 cells have long been 
used for autophagy research and are known to be highly sensitive to autophagy [1-7]. It is also 
known that several types of cancer cell are resistant to chemotherapeutic agents that are potent 
apoptosis inducers [8]. HCC including HepG2 cells are resistant to apoptosis because of the 
high expression of B-cell lymphoma-extra-large, which is an antiapoptotic member of the B-
cell lymphoma-2 (Bcl-2) family [9]. Therefore, HepG2 cells are suitable for this study to 
identify crude extracts modulating autophagy under conditions of apoptosis resistance. 
We first established an assay for analyzing autophagy and antiproliferation using 3-MA, 
CQ, and BBR as compounds that modulate autophagy in HepG2 cells. Next, we screened 130 
different crude extracts. Finally, we investigated the effects of the selected crude extracts on 
cell proliferation and autophagy modulation. 
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2.2. Materials and methods 
2.2.1. Preparation of crude extracts 
All crude drugs were purchased from one of the following manufacturers, respectively; 
Daido Pharmaceutical Co., Ltd. (Daido: Toyama, Japan); Kinokuniya Han Pharmacy 
(Kinokuniya: Tokyo, Japan); Kojima Kampo Co., Ltd. (Kojima: Osaka, Japan); MATSUURA 
YAKUGYO Co., Ltd. (Matsuura: Aichi, Japan); Tochimoto Tenkaido Co., Ltd. (Tochimoto: 
Osaka, Japan); Takasago Pharmaceutical Co., Ltd. (Takasago: Osaka, Japan); or UCHIDA 
WAKANYAKU Ltd. (Uchida: Tokyo, Japan). See Table 2.1 for details. All crude drug samples 
met the grade standards of the Japanese Pharmacopoeia 17th Edition (Pharmaceutical and 
Medical Device Regulatory Science Society of Japan, 2016) or the Japanese standards for non-
Pharmacopoeial crude drugs 2018. The quality managers of each manufacturer identified and 
certificated the plant species. Five grams was extracted from each crude drug overnight at room 
temperature using methanol (MeOH). The supernatant was evaporated under nitrogen gas to 
obtain the crude extract. The crude extracts were dissolved in dimethyl sulfoxide (DMSO) as a 
stock solution at a concentration of 100 mg/mL and stored at −20 °C. 
 
2.2.2. Reagents 
BBR (purity > 90%), Etoposide (ETP, purity > 98%), and 3-MA (purity > 98%) were 
purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan). CQ (purity > 
98%) was purchased from Nacalai Tesque Industries (Kyoto, Japan). Antibodies against LC3B 
and p62 were obtained from Cell Signaling Technology (Beverly, MA, USA). The antibody 
against β-actin and RIPA lysis buffer were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Fetal bovine serum (FBS) was purchased from GIBCO (Gaithersburg, MD, 
USA). All other materials were obtained from FUJIFILM Wako Pure Chemical Corporation. 
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2.2.3. Cell culture and treatment 
HepG2 cells were obtained from the RIKEN BioResource Center Cell Bank (Ibaraki, 
Japan). The cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% FBS and 1% penicillin-streptomycin-L-glutamine and incubated at 37 °C with 5% 
CO2 under fully humidified conditions. During the cell treatments, the concentration of DMSO 
in the cell culture medium did not exceed 0.2% (v/v), and the controls were always treated with 
the same amount of DMSO as was used in the corresponding experiments. 
 
2.2.4. Western blot analysis 
Cells (1 × 106 cells/dish) were plated on 6 cm dishes. After replacing with fresh medium, 
the cells were treated with each crude extract or BBR for various time periods, after which they 
were harvested and lysed in RIPA lysis buffer containing protease and phosphatase inhibitors. 
After centrifugation for 15 min at 12,000 × g and 4 °C, the protein content of the samples was 
determined using a dye-binding protein assay kit, following the manufacturer’s instructions 
(Bio-Rad, Richmond, CA, USA). Equal amounts of lysate protein were subjected to SDS-PAGE. 
The proteins were electrotransferred to PVDF membranes and detected as previously described 
[10]. BBR was then used as a positive control [3,4]. The relative intensity of the indicated band 
was quantified using ImageJ software (1.50i; Java 1.6.0_24 (64-bit), National Institutes of 
Health, Bethesda, MD, USA), and the value was normalized to corresponding loading control 
and expressed as the fold change in the control group. 
 
2.2.5. Determination of cell proliferation 
Cell proliferation was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. The number of 0.9 × 104 cells/well were cultured 
on 96-well plates. After replacing the original medium with a fresh medium, the cells were 
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treated with various concentrations of each crude extract for 24 h. At the end of treatment, 10 
μL of 5 mg/mL MTT solution was added to each well, and the cells were incubated for another 
4 h. The precipitated MTT-formazan was dissolved in 100 μL of 0.04 N HCl-isopropanol, and 
the amount of formazan was measured at 595 nm using an iMark microplate reader (Bio-Rad, 
Tokyo, Japan). Cell proliferation was expressed as a percentage of that for the control culture. 
 
2.2.6. Statistical analysis 
All data were derived from at least three independent treatment repetitions. The results are 
expressed as the mean S.D. under each condition. The data were analyzed by ANOVA 
followed by Tukey’s test using GraphPad Prism 6 software (San Diego, CA, USA), and p < 
0.05 was considered statistically significant. 
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2.3. Results 
2.3.1. Establishment of an assay for autophagy-mediated cell survival 
As described in Chapter 1.3, 3-MA and CQ are known as autophagy inhibitors. 3-MA 
inhibits the early-stage of autophagy by suppressing autophagosome maturation [1]. On the 
other hand, CQ blocks the late-stage of autophagy by inhibiting proteolytic degradation [1]. To 
define the stages of autophagy inhibition that can be evaluated in this assay, we first examined 
the effects of 3-MA and CQ on each autophagy-related protein. The expression level of LC3-II 
generally correlates with the number of autophagosomes [11, 12]. Thus, we examined the effect 
of 3-MA and CQ on LC3-II levels in HepG2 cells. The cells were treated with 3-MA at 5 mM 
or CQ at 25 μM for various time periods, respectively. Protein levels were examined using 
western blotting. As shown in Fig. 2.1A, 3-MA showed a weak induction of LC3-II level. 
Conversely, CQ showed a clear increase of LC3-II level. 
To confirm that 3-MA and CQ are related to autophagy, it was necessary to determine the 
autophagic flux assessed by monitoring p62 levels. p62 directly interacts with LC3 on the 
isolated membrane, and subsequently p62 is incorporated into the autophagosome and then 
degraded [13, 14]. Previously, it was reported that the accumulation of p62 occurs when the 
late-stage of autophagy is inhibited [1, 6]. Therefore, we conducted a time-course experiment 
to determine the effect of 3-MA and CQ on p62 levels. As shown in Fig. 2.1B, 3-MA showed 
no apparent accumulation of p62, and conversely, CQ showed a clear accumulation of p62. 
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In previous studies, we reported that BBR (see page 9, Chapter 1, Fig. 1.3), an isoquinoline 
alkaloid contained in Coptis japonica and Phellodendron amurense, suppresses the 
proliferation of HL-60 cells [15]. It has been reported that BBR causes autophagic cell death 
by excessively inducing autophagy in HepG2 cells [3, 4]. Based on the above, we established 
an assay for analyses of autophagy and antiproliferation using BBR as an autophagy-inducing 
compound. First, we examined the effect of BBR on LC3-II level in HepG2 cells. The cells 
were treated with BBR at 10 and 50 μM for 24 h. As shown in Fig. 2.2A, BBR treatment 
remarkably increased LC3-II level at 50 μM. Next, to examine the optimum time for treatment, 
Figure 2.1. Effects of 3-MA and CQ on LC3-II and p62 expression levels. HepG2 
cells were treated with 3-MA (5 mM) or CQ (25 µM) for the times indicated. The 
expression levels of LC3B (A), p62 (B), and β-actin were determined by western 
blotting. Relative intensity of p62 is shown as a bar graph. The data shown are 
representative of three independent treatments using the same parameters with similar 
results. 
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the cells were treated with BBR at 50 μM for various time periods. As shown in Fig. 2.2B, BBR 
increased LC3-II level when the treatment time was more than 18 h; thus, we decided to treat 
the cells with each crude extract for 24 h to evaluate the expression level of LC3-II. 
 
 
 
 
 
It has been suggested that autophagy is intimately related to the proliferation of cancer 
cells [3-6, 16-20]; therefore, we next investigated the effects of BBR on the proliferation of 
HepG2 cells. The cells were treated with BBR at various concentrations for 24 or 48 h, and cell 
proliferations were determined using MTT assay. As shown in Fig. 2.3, significant decrease in 
the proliferation of HepG2 cells was observed in the presence of BBR. 
 
 
 
 
Figure 2.2. Effect of BBR on LC3-II expression levels. HepG2 cells were treated 
with 10 or 50 µM BBR for 24 h (A), and cells were treated with BBR (50 µM) for the 
times indicated (B). The expression levels of LC3B and β-actin were determined by 
western blotting. The data shown are representative of three independent treatments 
using the same parameters with similar results. 
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As with 3-MA and CQ, we conducted a time-course experiment to determine the effect of 
BBR on p62 level. Previously, it was reported that p62 is rapidly degraded by the 
autophagosome when autophagy is activated by starvation, and then recovers to basal levels 
after several hours in HepG2 cells [22]. As shown in Fig. 2.4, BBR temporarily decreased p62 
level upon a short period of incubation (approximately 4 h) and then the level recovered to basal 
level after 12 h. Therefore, the p62 levels with BBR treatment were consistent with the 
autophagy-inducing characteristics; these results agree with previous studies indicating that 
BBR induces autophagy.  
 
Figure 2.3. Effect of BBR on cell proliferation. HepG2 cells were treated with BBR 
at various concentrations for 48 h (A), and cells were treated with BBR (50 µM) for 
the times indicated (B) and cell proliferations were determined using MTT assay. ETP 
was used as a model for inducing apoptotic cell death against HepG2 cells [21]. The 
data are presented as the mean  S.D. of three individual experiments. ∗p < 0.05 
compared with the control group. 
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As described above, we decided to apply this assay established using 3-MA, CQ, and BBR 
to screen each crude extract for the investigation of autophagic activity. As shown in Table 2.2, 
this assay can divide crude extracts into autophagy inducers or late-stage inhibitors by the 
observation of LC3-II level. Subsequently, the results of p62 accumulation by extracts can 
determine autophagy inducers or late-stage inhibitors. 
 
  
Figure 2.4. Effect of BBR on p62 expression levels. HepG2 cells were treated with 
BBR (50 M) for the times indicated. The expression levels of p62 and β-actin were 
determined by western blotting. Relative intensity of p62 is shown as a bar graph. The 
data shown are representative of three independent treatments using the same 
parameters with similar results. 
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Table 2.2. Effects of each autophagy modulator on LC3-II and p62 expression levels. 
Modulation of autophagy Modulator LC3-II p62 
Inhibition 
Early-stage 3-MA   
Late-stage CQ   
Induction 
Starvation [22]   or  
BBR   or  
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2.3.2. Effects of 130 crude extracts on autophagosome formation 
We next investigated the effects of MeOH extracts prepared from the crude drugs on the 
levels of LC3-II in HepG2 cells. The cells were treated with 130 crude extracts at 20 μg/mL for 
24 h. LC3-II levels were examined using western blotting, and the band intensities were 
quantified and expressed as the fold changes relative to those in the control. BBR was used as 
a positive control (Fig. 2.2). As shown in Fig. 2.5A and B, among the 130 crude extracts, 24 
crude extracts, which are shown in black stars and columns, increased LC3-II levels, which 
suggests that they might exhibit modulation of autophagy. 
 
 
 
 
 
Figure 2.5. Cont. 
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Figure 2.5. Effects of 130 crude extracts on LC3-II expression levels. All raw data 
(A) and relative intensity of LC3-II expression levels by 130 crude extracts (B). 
Notable increases are shown by a black star (★) (A) and black column (B). HepG2 
cells were treated with 20 µg/mL of each crude extract for 24 h, and the expression 
levels of LC3B and β-actin were determined by western blotting. The data shown are 
representative of three independent treatments using the same parameters with similar 
results. Note: BBR, positive control (BBR 50 μM); 1–130, crude drug number (see 
Table 2.1). 
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2.3.3. Effects of 24 crude extracts on cell proliferation 
We further investigated the effects of the selected 24 crude extracts on the proliferation of 
HepG2 cells. The cells were treated with 5, 10, and 20 μg/mL of each of the 24 crude extracts 
for 24 h, and cell proliferation was measured using MTT assay. Table 2.3 indicates the 
percentage of cell proliferation after treatment with 5, 10, and 20 μg/mL of each extract. Among 
the 24 crude extracts, cell proliferation was significantly suppressed by >10% compared with 
that in the control using the following five crude extracts: 41 (Goboshi; burdock fruit), 75 
(Soboku; sappan wood), 118 (Mokko; saussurea root), 125 (Rengyo; forsythia fruit), and 130 
(Hikai; dioscorea). On the other hand, three extracts, namely, 102 (Hishinomi; water chestnut), 
106 (Biwayo; loquat leaf), and 107 (Binroji; areca), increased cell proliferation by >10% 
compared with that of the control. The remaining 16 crude extracts had no effect on cell 
proliferation. Fig. 2.6 shows the cell proliferation of only eight crude extracts (five extracts that 
suppressed cell proliferation and three extracts that increased it). These results suggest that these 
eight crude drugs might influence cell proliferation and autophagy. 
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Table 2.3. Effects of selected 24 crude extracts on cell proliferation. 
Drug 
No. 
Japanese Name English Name 
Concentration (µg/mL) 
5 10 20 
5 Uzu Aconite Root 100.4 100.3 103.3 
12 Onji Polygala Root 100.4 97.3 96.4 
17 Kakko Pogostemon Herb 96.6 100.2 100.5 
18 Kakkon Pueraria Root 101.6 107.4 109.5 
24 Kikyo Platycodon Root 103.6 106.9 106.8 
41b) Goboshi Burdock Fruit 89.5 82.9 76.7 
42 Gomishi Schisandra Fruit 105.5 107.3 106.2 
43 Saiko Bupleurum Root 100.8 100.3 96.1 
61 Jashoshi Cnidium Monnieri Fruit 96.1 96.1 92.6 
68 Shoma Cimicifuga Rhizome 100.2 104.3 106.3 
72 Sentai Cicada Slough 105.6 103.2 101.4 
75 b) Soboku Sappan Wood 100.8 94.0 86.9 
76 Soyo Perilla Herb 102.7 103.8 105.9 
82 Chimo Anemarrhena Rhizome 99.4 100.8 96.9 
102 a) Hishinomi Water Chestnut 105.1 108.1 116.3 
106 a) Biwayo Loquat Leaf 106.9 110.7 113.9 
107 a) Binroji Areca 105.1 114.6 108.7 
114 Mao Ephedra Herb 101.5 95.0 97.7 
118 b) Mokko Saussurea Root 94.2 82.3 67.3 
124 Ryokyo 
Alpinia Officinarum 
Rhizome 
101.4 103.2 109.5 
125 b) Rengyo Forsythia Fruit 90.4 89.5 88.7 
126 Renniku Nelumbo Seed 103.5 105.6 103.2 
127 Tanjin Salvia Miltiorrhiza Root 98.2 99.8 95.3 
130 b) Hikai Dioscorea 71.8 50.1 20.0 
a)Extracts that increased cell proliferation by >10% compared with the control. b)Extracts that 
suppressed cell proliferation by >10% compared with the control. 
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2.3.4. Effects of five crude extracts on autophagy flux 
Fig. 2.7 shows p62 levels upon treatment with five crude extracts suppressing cell 
proliferation. All of these crude extracts increased p62 levels. In particular, Hikai (130) strongly 
induced p62 level by more than fourfold after treatments for 12 and 24 h. Mokko (118) also 
induced p62 level by more than fourfold after treatment for 12 h. These results suggest that 
Goboshi (41), Soboku (75), Mokko (118), Rengyo (125), and Hikai (130) deregulate the 
autophagic pathway by blocking autophagic flux, which results in p62 accumulation. 
 
 
Figure 2.6. Effects of eight crude extracts on cell proliferation. HepG2 cells were 
treated with each crude extract at various concentrations for 24 h (A), and cells were 
treated with each crude extract (20 μg/mL) for the times indicated (B) and cell 
proliferations were determined using MTT assay. The data are presented as the mean 
± S.D. of three individual experiments. ∗p < 0.05 compared with the control group. 
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Figure 2.7. Effects of five crude extracts on p62 expression levels. HepG2 cells were 
treated with 20 µg/mL of each crude extract for different durations. The expression levels of 
p62 and β-actin were determined by western blotting. The data shown are representative of 
three independent treatments using the same parameters with similar results. 
36
 Chapter Two 
2.3.5. Effects of three crude extracts on autophagy flux 
Fig. 2.8 indicates p62 levels regulated by the three crude extracts that increased cell 
proliferation. Hishinomi (102) and Biwayo (106) had no effect on p62 levels during treatment. 
Binroji (107) decreased p62 level within a short time (approximately 4 h) after treatment and 
then p62 level recovered to basal level after 12 h. The results of these studies suggest that 
Hishinomi (102), Biwayo (106), and Binroji (107) did not block autophagic flux. Furthermore, 
Binroji (107) clearly induced autophagy.  
 
 
 
 
Figure 2.8. Effects of three crude extracts on p62 expression levels. HepG2 cells 
were treated with each crude extract at the indicated concentrations and for different 
durations. The expression levels of p62 and β-actin were determined by western 
blotting. The data shown are representative of three independent treatments using the 
same parameters with similar results. 
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2.4. Discussion 
As described in this chapter, we screened 130 extracts prepared from different crude drugs 
to identify those crude drugs that modulate HepG2 proliferation and autophagy. First, we 
screened 130 crude extracts to select those that increased LC3-II levels. Among them, 24 crude 
extracts did so, which suggests that these extracts might modulate autophagy. On the other hand, 
several crude extracts reduced LC3-II levels. These crude extracts may contain inhibitors of 
early-stage autophagy, but we did not focus on these crude extracts in this thesis. This is because 
these crude extracts are uncertain to contain autophagy inducers and inhibitors of late-stage that 
increased LC3-II levels. Therefore, we focused on crude extracts increasing LC3-II levels for 
effective search of autophagy modulators. 
Among the 24 crude extracts increased LC3-II levels, three extracts induced cell growth, 
but five extracts suppressed cell proliferation. Interestingly, the remaining 16 crude extracts had 
no effect on cell proliferation despite increasing LC3-II levels. These results suggest that the 
regulation of HepG2 proliferation is not indispensable for LC3-II induction. We determined 
that autophagic flux could be assessed by monitoring p62 levels because the results of screening 
for LC3-II levels cannot be directly applied to the selection of extracts that inhibit autophagy. 
Among the three crude extracts increased cell proliferation, Hishinomi (102) and Biwayo (106) 
had no effect on p62 levels. On the other hand, Binroji (107) decreased p62 level within a short 
duration after treatment, and then the level finally recovered to their basal level. It appears that 
Binroji (107) induced cell growth with inducing autophagy, and we expect that this crude drug 
might contain compounds that are specific inducers of autophagy. Although Hishinomi (102) 
and Biwayo (106) did not show obvious induction of autophagy, they showed that LC3-II levels 
can be increased without blocking autophagic flux. These results probably reflect that 
Hishinomi (102) and Biwayo (106) induced cell growth with inducing autophagy, but further 
investigations are needed to confirm these findings. In fact, Binroji (107) has been reported to 
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induce autophagy in several cell lines, such as leukemic Jurkat T cells [23] and oral carcinoma 
cells (OECM-1), Cal-27, and Scc-9 [24], by activating the AMPK/mTOR signaling pathway 
after the accumulation of reactive oxygen species [24]. However, the relationship between 
autophagy and Hishinomi (102) or Biwayo (106) has not been previously reported. 
On the other hand, five crude extracts suppressed cell proliferation and increased p62 
levels, which suggests that these extracts disturb the autophagic pathway by inhibiting 
autophagic flux, leading to p62 accumulation. Among these five extracts, Goboshi (41) and 
Rengyo (125) contain arctigenin belonging to lignans as the same major compound. It has been 
reported that arctigenin protects against drug-induced hepatitis by suppressing the immune 
system and modulating autophagy by inhibiting the IFN-γ/IL-6/Stat1 and IL-6/Bnip3 pathways 
in mice [25]. However, our results in this study indicate that Soboku (75) and Mokko (118) 
inhibited autophagy with p62 accumulation. Brazilin contained in Soboku (75) was reported to 
induce autophagic cell death by disturbing calcium homeostasis in osteosarcoma MG-63 cells, 
thereby suppressing cell proliferation [26]. Costunolide contained in Mokko (118) was reported 
to suppress the proliferation of multidrug-resistant human ovarian cancer OAW42-A cells by 
activating apoptotic and autophagic pathways via the decreased expression of Bcl-2 [27]. This 
implies that the differences in the reactivity and signaling pathways depend on the cell type. 
Our results and those of previous reports indicate that these extracts contain compounds that 
modulate autophagy. We conclude that the crude drugs selected for this study could serve as 
sources of lead compounds in the development of reagents for autophagy research and agents 
for cancer therapy. However, further studies are needed to isolate and identify the active 
compounds in the drugs. 
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2.5. Conclusion 
Among the 130 crude extracts, 24 increased LC3-II levels. Among these, Goboshi 
(burdock fruit), Soboku (sappan wood), Mokko (saussurea root), Rengyo (forsythia fruit), and 
Hikai (dioscorea) notably suppressed the proliferation of HepG2 cells and increased p62 levels, 
which suggested that these five extracts disturb autophagy, resulting in p62 accumulation. On 
the other hand, Hishinomi (water chestnut), Biwayo (loquat leaf), and Binroji (areca) induced 
cell growth and decreased or did not affect p62 levels, which implied that these three extracts 
might induce autophagy modulators for cell growth. The results suggest that the compounds, 
which are contained in the crude drugs selected for this study, could control cell proliferation 
with modulating autophagy in HepG2 cells. The isolation and identification of the active 
compounds in these drugs might lead to the development of reagents for autophagy research 
and agents for cancer therapy. 
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Chapter 3 
Suppression of autophagy by arctigenin contained in the fruits of 
Arctium lappa (Goboshi) and the fruits of Forsythia suspense 
(Rengyo) and the molecular mechanisms 
 
3.1. Introduction 
As described in Chapter 2, the screening data demonstrated that extracts of the fruits of 
Arctium lappa (hereafter, Goboshi) and the fruits of Forsythia suspensa (hereafter, Rengyo) 
have beneficial antiproliferative activity with inhibition of autophagy (Fig. 3.1 and 3.2) [1].  
 
 
 
 
Figure 3.1. The flower [2] and the fruits of Arctium lappa (Goboshi). 
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Goboshi has the following pharmacological activities: anti-inflammatory, antibacterial, 
antiviral, antioxidant, neuro-and hepatoprotective, antitumor, and antiaging [3, 4]. Rengyo has 
anti-inflammatory, antibacterial, antiviral, antioxidant, neuro- and hepato-protective, antitumor, 
and anti-atopic dermatitis effects [5, 6]. It is well known that the major compounds of both 
Goboshi and Rengyo are arctigenin (ARG) and arctiin (ARC) (Fig. 3.3) [7].  
 
 
 
 
 
Figure 3.2. The flower [2] and the fruits of Forsythia suspense (Rengyo). 
Figure 3.3. Chemical structures of ARG and ARC. 
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ARG and ARC are bioactive lignans with multiple pharmacological functions such as 
antitumor [8], antioxidant [9], anti-inflammatory [10], antiviral [11], and neuroprotective effects 
[12]. Recently, ARG was reported to induce autophagic cell death by inhibiting activation of 
the mTOR pathway in ER-positive human breast cancer cells [13]. However, it seems likely 
that ARG could modulate autophagy (induce or inhibit), but its mechanism of action in cancer 
cells is not fully understood.  
As described in this chapter, we first examined the effects of ARG and ARC on the 
proliferation of HepG2 cells. Next, we investigated the efficacy and molecular mechanism of 
action of ARG on the modulation of autophagy-related proteins in HepG2 and human breast 
cancer MCF-7 cells. Furthermore, we confirmed the suppressive effect of ARG on starvation-
induced autophagy. 
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3.2. Materials and methods 
3.2.1. Reagents 
ARG (purity > 95%) and ARC (purity > 97%) were purchased from Tokyo Chemical 
Industries (Tokyo, Japan). Antibodies against beclin 1, phospho-beclin 1 (Ser93) (p-beclin 1), 
caspase-3, and PARP were obtained from Cell Signaling Technology (Beverly, MA, USA). The 
anti-rabbit Alexa Fluor 488-conjugated antibody was purchased from Thermo Fisher Scientific 
(Rockford, IL, USA). The ProLong® Gold antifade reagent with 4',6-diamidino-2-phenylindole 
(DAPI) was obtained from Invitrogen (Carlsbad, CA, USA). Triton X-100 was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). All other reagents were the same as described in Chapter 
2.2.2. 
 
3.2.2. Cell culture and treatment 
HepG2 and MCF-7 cells were obtained from the RIKEN BioResource Center Cell Bank 
(Ibaraki, Japan). Both cells were grown in DMEM (regular medium). The cell culture and 
treatment were performed as explained in Chapter 2.2.3. To induce starvation, cells were 
washed with phosphate-buffered saline (PBS) and incubated in amino acid-free DMEM without 
FBS (starvation medium). 
 
3.2.3. Determination of cell proliferation 
See Chapter 2.2.5. After replacing the original medium with fresh regular medium, the 
cells were treated with various concentrations of ARG or ARC for 24 or 48 h. Determination 
of cell proliferation was performed same MTT assay protocol as described in Chapter 2.2.5. 
 
3.2.4. Western blot analysis 
See Chapter 2.2.4. 
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3.2.5. Fluorescence microscopy 
Cells (5 × 104 cells) were plated in two-chamber glass slides in 2 mL of regular medium. 
After replacing with starvation medium, the cells were incubated with ARG for 4 h. Then, the 
cells were fixed with 4% paraformaldehyde for 15 min and permeabilized with 0.3% (v/v) 
Triton X-100 in PBS for 10 min. After washing with PBS, the cells were blocked with PBS 
containing 0.3% (v/v) Triton X-100 and 1% (w/v) bovine serum albumin for 60 min and 
incubated with anti-LC3B antibody (1:200) for 1 h. After washing, the cells were incubated 
with secondary anti-rabbit Alexa Fluor 488-conjugated antibody (1:1000) for 30 min in the dark. 
Then, the slide was rinsed with PBS and mounted with ProLong® Gold antifade reagent with 
DAPI. The slides were observed using a confocal laser scanning microscope (FV10i; Olympus, 
Tokyo, Japan). 
 
3.2.6. Statistical analysis 
See Chapter 2.2.6. 
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3.3. Results 
3.3.1. Effects of ARG and ARC on cell proliferation 
First, we examined the effects of ARG and ARC on the proliferation of HepG2 cells. The 
cells were treated with ARG or ARC at several concentrations for 24 or 48 h, after which cell 
proliferation was determined using MTT assay. As shown in Fig. 3.4, ARG or ARC 
significantly suppressed cell proliferation. The antiproliferative effect of ARG was higher than 
that of ARC. 
 
 
 
 
 
 
Figure 3.4. Effects of ARG and ARC on cell proliferation. HepG2 cells were treated with 
ARG or ARC at various concentrations for 48 h (A), and cells were treated with ARG (10 
µM) or ARC (10 µM) for the times indicated (B) and cell proliferations were determined 
using MTT assay. ETP was used as a model for inducing apoptotic cell death against HepG2 
cells. The data are presented as the mean S.D. of three individual experiments. p < 0.05 
compared with the control group. 
49
 Chapter Three 
3.3.2. Effect of ARG on autophagy-related proteins 
Next, we determined the effect of ARG on the expression levels of autophagy-related 
proteins by western blotting. Beclin 1, which is also one of the most important proteins for 
autophagy, is directly phosphorylated by AMPK to induce autophagy [14]. Thus, an increase in 
the level of p-beclin 1 indicates induction of autophagy. As shown in Fig. 3.5, ARG slightly 
increased LC3-II level and enhanced the phosphorylation of beclin 1. 
 
 
 
 
 
 
 
 
Figure 3.5. Effect of ARG on autophagy-related proteins. HepG2 cells were treated with 
ARG at the indicated concentrations for 24 h. The expression levels of LC3B, beclin 1, p-
beclin 1, p62, and β-actin were determined by western blotting. The data shown are 
representative of three independent treatments using the same parameters with similar 
results. 
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To assess whether ARG induces or inhibits autophagy, we performed time-course 
experiments to determine the effect of ARG on p62 levels. As shown in Fig. 3.6, ARG clearly 
increased p62 level as time passes. To confirm the results obtained, we used a different cancer 
cell line, human breast cancer MCF-7 cells. As shown in Fig. 3.7, ARG suppressed cell 
proliferation and slightly increased LC3-II level and significantly increased p-beclin 1 and p62 
levels in MCF-7 cells. These results suggest that ARG might block the autophagic pathway, 
which leads to p62 accumulation. 
 
 
 
 
 
 
 
Figure 3.6. Effect of ARG on p62 expression levels. HepG2 cells were treated with 
ARG (10 M) for the times indicated. The expression levels of p62 and β-actin were 
determined by western blotting. Relative intensity of p62 is shown as a bar graph. 
The data shown are representative of three independent treatments using the same 
parameters with similar results. 
51
 Chapter Three 
 
 
 
 
 
 
As shown in Fig. 3.8, 3-MA slightly increased both LC3-II and p-beclin 1 levels, but not 
p62 accumulation. Moreover, CQ clearly increased both LC3-II and p62 levels, but not beclin 
1 phosphorylation. Taken together, our data imply that the stage of inhibition of autophagy by 
ARG differed from those by 3-MA or CQ. 
 
 
 
Figure 3.7. Effect of ARG on proliferation of MCF-7 cells and autophagy-related 
proteins. MCF-7 cells were treated with ARG at various concentrations for 24 or 48 h, and 
cell proliferations were determined using MTT assay (A). The data are presented as the mean 
 S.D. of three individual experiments. ∗p < 0.05 compared with the control group. MCF-7 
cells were treated with ARG at various concentrations for 24 h (B). The expression levels of 
LC3B, beclin 1, p-beclin 1, p62, and β-actin were determined by western blotting. The data 
shown are representative of three independent treatments using the same parameters with 
similar results. 
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Figure 3.8. Effects of 3-MA and CQ on autophagy-related proteins. HepG2 cells were 
treated with 3-MA and CQ at the indicated concentrations for 24 h. The expression levels of 
LC3B, beclin 1, p-beclin 1, p62, and β-actin were determined by western blotting. The data 
shown are representative of three independent treatments using the same parameters with 
similar results. 
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3.3.3. Effect of ARG on starvation-induced autophagy 
To confirm the autophagy inhibition by ARG, we further determined whether ARG could 
influence starvation-induced autophagy. First, we examined the levels of LC3-II in the absence 
or presence of ARG using HepG2 cells after 4 h of continuous starvation. As shown in Fig. 3.9, 
although starvation increased LC3-II level, ARG clearly reduced this induction.  
 
 
 
 
Figure 3.9. Effect of ARG on starvation-induced LC3-II expression levels. HepG2 cells 
were treated with or without ARG (10 M) under conditions of regular medium or starvation 
medium for 4 h. The expression levels of LC3B and β-actin were determined by western 
blotting. Relative intensity of LC3-II is shown as a bar graph. The data shown are 
representative of three independent treatments using the same parameters with similar 
results. 
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Next, we observed autophagosome/autolysosome formation using a confocal laser 
scanning microscope. We detected autophagosomes/autolysosomes using anti-LC3B primary 
antibody and anti-rabbit Alexa Fluor 488-conjugated secondary antibody (green). As shown in 
Fig. 3.10, starvation treatment formed autophagosomes/autolysosomes, but ARG clearly 
suppressed this formation. These results demonstrated that ARG could inhibit starvation-
induced autophagy. 
 
 
 
 
Figure 3.10. Effect of ARG on increased autophagosome/autolysosome formation by 
starvation. Detection of LC3B-positive organelles (autophagosomes/autolysosomes). 
HepG2 ells were treated with or without ARG (10 M) under conditions of regular medium 
or starvation medium for 4 h. After incubation, cells were fixed, permeabilized, and treated 
with anti-LC3B antibody followed by treatment with Alexa Fluor 488-conjugated secondary 
antibody. The images were made at ×250 magnification. 
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3.3.4. Effect of ARG on apoptosis-related proteins 
Caspase-3 activation and PARP cleavage are hallmarks of apoptosis [15-17]. To determine 
the involvement of ARG in apoptosis, we examined the effect of ARG on caspase-3 and PARP. 
ETP was used as a positive control [15, 18]. Although ETP induced caspase-3 activation and 
PARP cleavage, ARG did not affect either of these proteins, even at 100 M, which is ten times 
the concentration that modulates LC3-II and p-beclin 1 (Fig. 3.11). These results imply that the 
antiproliferative effect of ARG may occur independently of the caspase-3 mediated apoptosis. 
 
 
 
 
 
 
Figure 3.11. Effect of ARG on the activation of caspase-3 and PARP cleavage. HepG2 
cells were treated with ARG or ETP at the indicated concentrations for 24 h. The expression 
levels of caspase-3, PARP, and β-actin were determined by western blotting. ETP was used 
as a positive control. The data shown are representative of three independent treatments 
using the same parameters with similar results. 
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3.4. Discussion 
As described in this chapter, we found that ARG and ARC significantly suppressed the 
proliferation of HepG2 cells, and the antiproliferative effect of ARG was higher than that of 
ARC. Molecular analysis showed that ARG slightly increased LC3-II level and strongly 
induced beclin 1 phosphorylation and p62 level. In addition, we also observed similar patterns 
for beclin 1 phosphorylation and p62 level in human breast cancer MCF-7 cells. These results 
suggest that ARG might block the autophagic pathway, which leads to p62 accumulation. 
Starvation is the most potent known physiological inducer of autophagy, and it has been 
commonly used to study the molecular mechanism of autophagy [19]. Hence, we further 
verified the inhibitory effect of ARG on starvation-induced autophagy. Our data indicated that 
the expression of LC3-II was induced by starvation medium, but ARG clearly reduced this 
induction. Moreover, the data using confocal laser scanning microscopy demonstrated that 
autophagosomes/autolysosomes formed by starvation were decreased by ARG. These data 
suggest the autophagy inhibition by ARG. 
Several autophagy inhibitors have been developed to analyze the mechanism of autophagy 
and enhance the therapeutic effects of anticancer drugs. 3-MA and CQ are well-known 
autophagy inhibitors. 3-MA is one of the most commonly used inhibitors to suppress autophagy 
at an early-stage. It is reported that 3-MA acts as a PI3K inhibitor that suppresses class III PI3K 
activity required for autophagosome maturation [19]. Thus, 3-MA inhibits autophagy without 
affecting LC3-II and p62 levels [19]. Indeed, our data showed that 3-MA induced beclin 1 
phosphorylation, but not LC3-II and p62 levels. In contrast, CQ is known as an inhibitor to 
block autophagy at a late-stage [19]. CQ inhibits acidification inside the lysosome and disturbs 
autophagosome–lysosome fusion [19]. We demonstrated that CQ clearly increased the levels 
of both LC3-II and p62. Interestingly, ARG slightly increased LC3-II level and strongly induced 
beclin 1 phosphorylation and p62 level. 3-MA slightly increased LC3-II level. Both ARG and 
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3-MA lack significant induction of LC3-II, indicating a low number of autophagosomes. This 
suggested that ARG suppresses the stage prior to autophagosome maturation, similar to 3-MA. 
Furthermore, although p62 accumulation was not observed in 3-MA, ARG significantly 
induced p62 accumulation like CQ. These findings imply that the stage of inhibition in 
autophagy by ARG differed from those by 3-MA and CQ (Fig. 3.12). 
 
 
 
 
 
Apoptosis is one of the main factors reducing cell proliferation. Numerous studies have 
reported many kinds of natural products that trigger apoptosis in various cancer cell lines [16. 
17]. In recent years, it has been reported that several natural products induce autophagy in 
parallel with inducing apoptosis. For example, toxicarioside O derived from Antiaris toxicaria 
was found to induce both apoptosis and autophagy in the colorectal cancer cell lines HCT116 
and SW480 [20]. BBR also induces both apoptosis and autophagy in human glioma cell lines 
[21] and HepG2 cells [22]. In addition, sodium cantharidinate derived from Chinese blister 
Figure 3.12. Proposed mechanism of inhibition of autophagy by ARG, 3-MA, and CQ. 
The autophagy inhibition mechanism of ARG shown is guess based on this study. Further 
investigation is needed to clarify the mechanism of ARG. 
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beetle induces both apoptosis and autophagy in HepG2 cells [23]. Moreover, durmillone, a 
flavonoid in Millettia pachyloba, also activates both in human cervix adenocarcinoma HeLa 
cells and the breast cancer cell line MCF-7 [24]. However, there are few reports regarding 
natural products that specifically modulate only autophagy without affecting apoptosis. Here, 
our data demonstrated that treatment with ARG even at 100 M, which is ten times the 
concentration that modulates autophagy, did not activate caspase-3 and cleave of PARP. These 
results imply that the antiproliferative activity of ARG may occur independently of caspase-3 
mediated apoptosis. 
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3.5. Conclusion 
In this chapter, we explored the effect of ARG, a bioactive lignan from both Goboshi and 
Rengyo, on cell proliferation and autophagy-related proteins in HepG2 cells. ARG suppressed 
the proliferation of HepG2 cells. Analysis of autophagy-related proteins using HepG2 and 
MCF-7 cells demonstrated that ARG might block the autophagy that leads to p62 accumulation. 
The stages of inhibition in autophagy by ARG differed from those by the autophagy inhibitors 
3-MA or CQ. ARG could also inhibit starvation-induced autophagy. Further analysis of 
apoptosis-related proteins indicated that ARG did not affect caspase-3 activation and PARP 
cleavage, suggesting that the antiproliferative activity of ARG can occur independently of 
caspase-3 mediated apoptosis. In summary, we conclude that ARG suppresses cell proliferation 
and autophagy in HepG2 cells. 
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Chapter 4 
Isolation of active compounds derived from the rhizome of 
Dioscorea tokoro (Hikai) that inhibit autophagy 
 
4.1. Introduction 
As described in Chapter 2, the screening data demonstrated that the extract of the rhizome 
of Dioscorea tokoro (hereafter, Hikai) (Fig. 4.1) exerted the strongest suppression on cell 
proliferation. 
 
 
 
 
Hikai, which is thought to have an effect on improving the circulation of water in the body 
(利水作用), has an anti-inflammatory effect, and is mainly used for treating dysuria, joint pain, 
and skin eczema, although it is rarely used. Hikai is a wild yam and its rhizomes are not 
generally used in the diet. However, in especially the north of Japan such as Iwate and Aomori 
prefectures, they are believed to be effective in recovering from fatigue and have been used to 
support health [2]. From chemical analyses, it has been reported that Hikai contains steroidal 
Figure 4.1. The flower [1] and the rhizome of Dioscorea tokoro (Hikai). 
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saponins such as dioscin and protodioscin [3, 4]. A report from pharmacological studies 
provided evidence that the MeOH extract of Hikai have a potential of treating rheumatoid 
arthritis [4]. However, data on the pharmacological activities of Hikai and its active compounds 
are very limited. 
As described in this chapter, we focused on the isolation of active compounds in Hikai 
exerting antiproliferative and inhibition of autophagy. First, we compared the activities of the 
fractions prepared from the MeOH extract of Hikai. The bioassay-guided fractionations of 
active fractions led to the isolation of several active compounds. Finally, we investigated the 
effects of isolated compounds on cell proliferation to explore the structure–activity relationship 
and confirmed the inhibition of autophagy. 
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4.2. Materials and methods 
4.2.1. General procedures 
Specific rotations were measured with a DIP-360 digital polarimeter (JASCO, Easton, PA, 
USA). Nuclear magnetic resonance (NMR) spectra were recorded on a JEOL ECX 400 FT-
NMR spectrometer (JEOL, Tokyo, Japan) at room temperature. Electrospray ionization time-
of-flight mass spectrometer (ESI-TOF-MS) experiments employed a Waters Xevo G2-XS Q-
TOF mass spectrometer (Waters, Milford, MA, USA). Column chromatography was performed 
on Silica Gel 60 (Nacalai Tesque., Kyoto, Japan, 230-400 mesh) and YMC ODS-A gel (YMC 
Co. Ltd., Kyoto, Japan, 50 µm,). Thin-layer chromatography (TLC) was performed on TLC 
Silica gel 60F254 (Merck, Damstadt, Germany) and TLC Silica gel 60 RP-18 F254S (Merck, 
Damstadt, Germany) plates. Spots were visualized by spraying with 10% aq. sulfuric acid, 
followed by heating. HPLC (high performance liquid chromatography) was performed on UV-
8020 UV-VIS detector (Tosoh Corp., Tokyo, Japan), DP-8020 pump (Tosoh Corp., Tokyo, 
Japan) and DP-8020 degasser (Tosoh Corp., Tokyo, Japan). XBridge BEH C18 Column (Waters, 
Milford, MA, USA, 130Å, 3.5 µm, 10 mm × 250 mm) were used for preparative purposes. 
 
4.2.2. Extraction and isolation 
Hikai (2.5 kg) was extracted three times with MeOH under reflux for 12 h. Evaporation of 
the solvent under reduced pressure provided a MeOH extract (338.77 g). A part of the MeOH 
extract (333.77 g) was partitioned into hexane–water (H2O) (1:1, v/v) mixture to furnish a 
hexane-soluble fraction (0.45 g) and an aqueous phase. The aqueous phase was further 
partitioned into ethyl acetate (EtOAc)–H2O (1:1, v/v) mixture to furnish an EtOAc-soluble 
fraction (19.23 g) and an aqueous phase. The aqueous phase was further extracted with n-
butanol (BuOH) to give an n-BuOH-soluble fraction (138.24 g) and an H2O-soluble fraction 
(124.17 g). A part of the n-BuOH-soluble fraction (21.15 g) was subjected to normal phase 
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silica gel column chromatography [580 g, chloroform–MeOH–H2O (20:3:1 → 15:3:1 → 
10:3:1 → 7:3:1 → 6:4:1, v/v/v, lower layer) → MeOH] to give 12 fractions [Fr. B1 (143.2 
mg), Fr. B2 (185.2 mg), Fr. B3 (437.6 mg), Fr. B4 (191.5 mg), Fr. B5 (266.9 mg), Fr. B6 (537.3 
mg), Fr. B7 (971.1 mg), Fr. B8 (5.14 g), Fr. B9 (2.07 g), Fr. B10 (2.67 g), Fr. B11 (6.24 g), Fr. 
B12 (1.39 g)]. Fraction B8 (5.14 g) was subjected to reversed –phase silica gel column 
chromatography [305 g, MeOH: H2O (7:3 →  8:2 →  9:1, v/v) →  MeOH] to give 14 
fractions [Fr. B8–1 (111.5 mg), Fr. B8–2 (32.6 mg), Fr. B8–3 (12.3 mg), Fr. B8–4 (17.4 mg) , 
Fr. B8–5 (18.7 mg), Fr. B8–6 (11.5 mg), Fr. B8–7 (152.1 mg), Fr. B8–8 (3.72 g) , Fr. B8–9 
(632.2 mg), Fr. B8–10 (15.7 mg), Fr. B8–11 (5.6 mg), Fr. B8–12 (5.2 g), Fr. B8–13 (14.9 mg), 
Fr. B8–14 (48.5 mg)]. Fraction B11 (6.24 g) was subjected to reversed–phase silica gel column 
chromatography [330 g, MeOH: H2O (5:5 → 6:4 → 7:3 → 8:2 →, v/v) → MeOH] to 
give 14 fractions [Fr. B11–1 (1.50 g), Fr. B11–2 (50.3 mg), Fr. B11–3 (46.9 mg), Fr. B11–4 
(54.8 mg) , Fr. B11–5 (221.4 mg), Fr. B11–6 (757.6 mg), Fr. B11–7 (1.10 g), Fr. B11–8 (1.51 
g), Fr. B11–9 (485.8 mg), Fr. B11–10 (201.7 mg), Fr. B11–11 (203.6 mg), Fr. B11–12 (139.3 
mg), Fr. B11–13 (30.5 mg), Fr. B11–14 (44.8 mg)]. A part of the Fr. B8–8 (200.0 mg) was 
purified by HPLC [acetonitrile: H2O: acetic acid (88:12:0.3), XBridge BEH C18] to give 1 
(63.9 mg, purity > 92%) and 2 (34.2 mg, purity > 90%). A part of the Fr. B11–8 (1.51 g) was 
purified by HPLC [acetonitrile: H2O: acetic acid (88:12:0.3), XBridge BEH C18] to give 3 
(29.4 mg, purity > 95%). The known compounds were identified by comparison of their 
physical data ([]D, 
1H-NMR, 13C-NMR, and MS) with reported values. 
 
4.2.3. Acid hydrolyses 
Compounds 1 and 2 (10.1 and 10.4 mg) were dissolved in 5 mL of 3 mol/L sulfuric acid 
and each solution was heated at 90 °C for 6 h. After neutralizing with sodium hydroxide, each 
hydrolysate was extracted 5 mL of ethyl acetate. Evaporation of the solvent under reduced 
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pressure yielded 4 (5.6 mg from 1, purity > 95%) and 5 (6.0 mg from 2, purity > 81%). Each 
compound was identified by comparison of their physical data ([]D, 
1H-NMR, 13C-NMR, and 
MS) with reported values.  
 
4.2.4. Materials for biological assays 
All materials using for biological assays were the same as described in Chapter 3.2.1. 
 
4.2.5. Cell culture and treatment 
See Chapter 2.2.3.  
 
4.2.6. Determination of cell proliferation 
The cell culture was performed as explained in Chapter 2.2.5. After replacing with fresh 
medium, the cells were treated with various concentrations of each fraction or each compound 
for 24 h. Determination of cell proliferation was performed same MTT assay protocol as 
described in Chapter 2.2.5. 
 
4.2.7. Western blot analysis 
Cells (1 × 106 cells/dish) were plated on 6 cm dishes. After replacing with fresh medium, 
the cells were treated with n-BuOH fraction or each compound for various time periods. All 
subsequent steps were performed same western blot analysis protocol as described in Chapter 
2.2.4. 
 
4.2.8. Statistical analysis 
See Chapter 2.2.6. 
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4.3. Results 
4.3.1. Comparison of antiproliferative effects of each fraction 
To identify the bioactive compounds responsible for the antiproliferative effect, the crude 
extract was suspended in water and successively partitioned using hexane, EtOAc, and n-BuOH. 
The cells were treated with 5, 10, and 20 μg/mL of each fraction for 24 h, and cell proliferation 
was measured using MTT assay. As shown in Fig. 4.2A, both n-BuOH and H2O fractions 
significantly suppressed cell proliferation compared with hexane and EtOAc fractions. To 
further determine which fraction exerts stronger effects, the cells were treated at much lower 
concentrations than 5 μg/mL of the n-BuOH and H2O fractions for 24 h (Fig. 4.2C). The results 
showed that the suppression of the n-BuOH fraction was stronger than that of the H2O fraction. 
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Figure 4.2. Effects of fractions prepared from Hikai extract on cell proliferation. 
HepG2 cells were treated with each fraction prepared from the crude extract of Hikai at 
various concentrations (A: 5–20 μg/mL, C: 0.313–5 μg/mL) for 24 h, and cells were treated 
with each fraction (B: 20 μg/mL, D: 0.625 μg/mL) for the times indicated and cell 
proliferations were determined using MTT assay. The data are represented as the mean 
S.D. of three individual experiments. ∗p < 0.05 compared with the control group. 
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4.3.2. Effect of n-BuOH fraction on autophagosome formation and autophagy flux 
To confirm the effect of n-BuOH fraction on autophagy, we observed the expression levels 
of both LC3-II and p62. The cells were treated with the n-BuOH fraction at 0.313 μg/mL for 
various time periods, and the levels of each protein were examined using western blotting. As 
shown in Fig. 4.3, treatment of the n-BuOH fraction clearly increased the levels of both LC3-
II and p62. These results suggest that the n-BuOH fraction might inhibits autophagy by blocking 
autophagic flux, which results in p62 and LC3-II accumulation. 
 
 
 
 
 
 
 
 
Figure 4.3. Effect of n-BuOH fraction on LC3-II and p62 expression levels. HepG2 cells 
were treated with n-BuOH fraction prepared from the crude extract of Hikai at 0.313 μg/mL 
for the times indicated. The expression levels of LC3B, p62, and β-actin were determined 
by western blotting. The data shown are representative of three independent treatments using 
the same parameters with similar results. 
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4.3.3. Isolation, acid hydrolyses, and structural identification of 1–5 
Since the n-BuOH fraction reduced cell proliferation most strongly and inhibited 
autophagy, we performed the isolation of bioactive compounds from the n-BuOH fraction. 
Further bioassay-guided separation using solvent partition, fractionation, and combined 
chromatography techniques was performed, and then we achieved the isolation of three 
compounds from the n-BuOH fraction. We isolated two spirostan-type steroidal saponins, 
dioscin (1) [5, 6], and yamogenin 3-O--L-rhamnopyranosyl(1→4)-O--L-rhamnopyranosyl 
(1→2)--D-glucopyranoside (2) [5, 7, 8], and a frostane-type steroidal saponins, protodioscin 
(3) [5, 9]. The structures were identified by physicochemical date including NMR and MS data, 
together with comparison those in the literature. In addition, 1 and 2 were acid-hydrolyzed to 
obtain each aglycone, diosgenin (4) [5, 10] and yamogenin (5) [5, 11]. The chemical structures 
of 1–5 are shown in Fig. 4.4. Among them, 1 and 3 are steroidal saponins that were well known 
as the main compounds from Hikai extract [3, 4, 12]. 
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4.3.4. Effects of 1–5 on cell proliferation, and its structure–activity relationships 
To investigate the effects of 1–5 on the proliferation of HepG2 cells, we treated the cells 
using 6.25, 12.5, 25, 50, and 100 μM of 1–5 for 24 h, followed by the MTT assay. When we 
compared the antiproliferative effect of each compound, all compounds reduced cell 
proliferation and the potency was in the following order: 1 > 2 > 3 > 4 > 5 (Fig. 4.5). 
The effects of 1 and 4 with a 25(R)-conformation were stronger than those of 2 and 5 with 
a 25(S)-conformation. These results indicated that the efficacy due to the 25(R)-conformation 
is maintained with or without the sugar moiety. Next, the effects of 1, 2, and 3 containing a 
sugar moiety were found to be stronger than those of 4 and 5 lacking one. In addition, 1 and 2, 
which possess a spirostan-type aglycone moiety, showed stronger effects than 3, which 
possesses a furostan-type aglycone moiety. From these results of structure–activity 
relationships, it was found that the 25(R)-conformation, structures containing a sugar moiety, 
and spirostan-type aglycone moiety might be important for antiproliferative effect. 
Figure 4.4. Chemical structures of 1–5 from n-BuOH fraction. 
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4.3.5. Effects of 1–5 on autophagosome formation and autophagy flux 
To determine whether 1–5 inhibit autophagy, we investigated their effects on the levels of 
both LC3-II and p62 in HepG2 cells. The cells were treated with 1 and 2 at 10 μM, 3 and 5 at 
50 μM, and 4 at 20 μM for various time periods. As shown in Fig. 4.6, the treatment with 1, 2, 
and 3 clearly increased the levels of both LC3-II and p62. These results suggest that 1, 2, and 3 
deregulate the autophagic pathway by blocking autophagic flux, which results in p62 and LC3-
II accumulation. On the other hand, the treatments with 4 and 5 did not show a clear increase 
in the levels of both LC3-II and p62. These results suggest that 4 and 5 do not affect autophagy. 
 
Figure 4.5. Effects of 1–5 on cell proliferation. HepG2 cells were treated with 1–5 at 
various concentrations for 24 h (A), and cells were treated with 1–5 (100 µM) for the times 
indicated (B), and cell proliferations were determined using MTT assay. ETP was used as a 
model for inducing apoptotic cell death against HepG2 cells. The data are presented as the 
mean  S.D. of three individual experiments. p < 0.05 compared with the control group. 
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Figure 4.6. Effects of 1–5 on LC3-II and p62 expression levels. HepG2 cells were treated 
with the indicated concentrations of 1–5 for 24 h (A), or different durations (B). The 
expression levels of LC3B (A), p62 (B), and β-actin were determined by western blotting. 
BBR (50 M) is a positive control. The data shown are representative of three independent 
treatments using the same parameters with similar results. 
(A) 
(B) 
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4.3.6. Effects of 1–3 on apoptosis-related proteins 
To determine whether the effects of 1, 2, and 3 regarding high antiproliferative effect are 
associated with apoptosis induction, we examined the effects of 1, 2, and 3 on caspase-3 and 
PARP. ETP was used as a positive control [13, 14]. As shown in Fig. 4.7, the treatments with 1 
and 2 at 10 μM, and 3 at 50 μM for 12 and 24 h did not induce the activation of caspase-3 and 
cleaved PARP, at all concentrations. These results suggest that the treatments with 1, 2, and 3 
did not induce caspase-3 mediated apoptosis in HepG2 cells. 
 
 
 
  
Figure 4.7. Effects of 1–3 on the activation of caspase-3 and PARP cleavage. HepG2 
cells were treated with the indicated concentrations of 1–3 for 12 or 24 h, respectively. The 
expression levels of caspase-3, PARP, and β-actin were determined by western blotting. ETP 
(100 M, 12 h) was used as a positive control. The data shown are representative of three 
independent treatments using the same parameters with similar results. 
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4.4. Discussion 
As described in this chapter, we aimed to isolate active compounds from Hikai or Hikai 
extract having antiproliferative activity and inhibition of autophagy. Among four fractions 
prepared by MeOH extract of Hikai, the medium-polar (n-BuOH) fraction exhibited stronger 
antiproliferative effect than the other three fractions (Fig. 4.2). In addition, the n-BuOH fraction 
increased the levels of both LC3-II and p62, leading to the inhibition of autophagy (Fig. 4.3). 
The bioassay-guided fractionations of active fractions led to the isolation of five compounds 
(1–5). Among these, 1 and 3 are well known as the main compounds of Hikai extract [3, 4]. 
Compounds 1–3 are steroidal saponins and 4 and 5 are produced by the acid hydrolysis of 1 
and 2 (Fig. 4.4). According to the results of cell proliferation analysis in HepG2 cells, 1–5 
exerted antiproliferative activity (Fig. 4.5). Moreover, structure–activity relationship analysis 
suggested that the 25(R)-conformation, structures containing a sugar moiety, and spirostan-type 
aglycone moiety might be important for antiproliferative activity. To confirm that 1–5 inhibit 
autophagy in HepG2 cells, the autophagic flux was assessed by monitoring p62 levels upon 
treatments with 1–5 for different times. Treatments with 1–3 deregulated the autophagic 
pathway by blocking autophagic flux, which resulted in p62 accumulation (Fig. 4.6). Similarly, 
the levels of LC3-II was increased upon treatment with 1–3, but not upon that with 4 and 5. 
These results suggested the importance of structures containing a sugar moiety in modulating 
autophagy with LC3-II and p62 accumulation. 
Although 1–3 exerted inhibitory activity on autophagy, these compounds did not show the 
activation of caspase-3 and the cleavage of PARP, which are characteristics of apoptosis 
induction (Fig. 4.7). These results suggest that the antiproliferative activity of 1–3 might be 
modulated by the inhibition of autophagy, but not the induction of caspase-3 mediated apoptosis. 
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4.5. Conclusion 
In this chapter, we found that the medium-polar (n-BuOH) to high-polar (H2O) fractions 
of Hikai exerted strong antiproliferative activity and inhibition of autophagy on HepG2 cells. 
Phytochemical investigations of the n-BuOH fraction achieved the isolation of steroidal 
saponins, dioscin (1), yamogenin 3-O--L-rhamnopyranosyl(1→4)-O--L-rhamno- pyranosyl 
(1→2)--D-glucopyranoside (2), and protodioscin (3). In addition, acid hydrolysis of 1 and 2 
produced each aglycone, diosgenin (4) and yamogenin (5), respectively. Structure-activity 
relationship analysis implied that a 25(R)-conformation, structures containing a sugar moiety, 
and spirostan-type aglycone moiety are important for antiproliferative activity. Analysis of 
autophagy-related proteins using HepG2 cells demonstrated that 1–3 might inhibit autophagy, 
leading to p62 accumulation.  
On the other hand, 1–3 did not affect caspase-3 activation and PARP cleavage, suggesting 
that the antiproliferative activity of 1–3 can occur independently of caspase-3 mediated 
apoptosis. Taking these findings together, we conclude that 1–3, active compounds in Hikai 
extract, suppresses cell proliferation and inhibited autophagy. 
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Chapter 5 
Inhibition of autophagy by major active compounds contained in 
the root of Saussurea lappa (Mokko) 
 
5.1. Introduction 
As described in Chapter 2, the screening data demonstrated that extract of the root of 
Saussurea lappa (hereafter, Mokko) (Fig. 5.1) exerted the second strongest suppression on cell 
proliferation.  
 
 
 
 
Mokko has been traditionally used in the alleviation of pain during abdominal distention 
and tenesmus, indigestion with anorexia, dysentery, nausea, and vomiting because it provides 
warming effects in the gastrointestinal tract [13]. Furthermore, in Japan, Korea, and China, 
Mokko extract is used for the management of asthma [4], inflammatory diseases [5, 6], and 
ulcers [7]. Previous studies have demonstrated that the extract of Mokko possesses anticancer 
activity on several cancer cell lines by inducing apoptosis in the AGS gastric cancer cells, 
Figure 5.1. The flower [1] and the root of Saussurea lappa (Mokko). 
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human prostate carcinoma LNCaP cells, KB human oral cancer cells, and androgen-insensitive 
human prostate cells [811]. As an attractive side, the Japanese name Mokko refers to “wood 
fragrance,” and Mokko has a reputation for its fragrance and use in perfumery, and Mokko 
extract is also used as aromatic stomachic medicine. 
Mokko contains up to 3% essential oil including principal sesquiterpene lactones, such as 
costunolide (CL) and dehydrocostuslactone (DCL) (Fig. 5.2) [2].  
 
 
 
 
Several of sesquiterpene lactones, including CL and DCL, were shown to possess various 
biological and pharmacological activities such as anti-inflammatory [12], antiulcer [4, 7], 
antiviral, and hepatoprotective effects [13]. Among them, CL and DCL are well known to 
possess anticancer effects. CL and DCL have been reported to induce apoptosis in the cell lines 
of prostate cancer [9, 11], oral cancer [10], lung cancer [14], breast cancer [15], hepatocellular 
carcinoma [16], colon cancer [17], neuroblastoma [18], and leukemia [19]. Although various 
beneficial pharmacological activities of CL and DCL have been clarified, the effects of CL and 
DCL on autophagy are still unclear.  
As described in this chapter, we aimed to determine the high antiproliferative activity and 
Figure 5.2. Chemical structures of CL and DCL. 
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the inhibition of autophagy exerted by the active compounds contained in Mokko on the HepG2 
cells. First, we compared the activities of the fractions prepared from the MeOH extract of 
Mokko. TLC and HPLC analyses of active fractions led to the confirming of CL and DCL 
containing. Finally, we investigated the effects of CL and DCL on cell proliferation and 
confirmed the inhibition of autophagy. 
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5.2. Materials and methods 
5.2.1. General procedures 
TLC was performed to same methods as described in Chapter 4.2.1. 
 
5.2.2. Extraction 
The roots of Saussurea lappa (3.0 kg) were extracted three times with MeOH under reflux 
for 12 h. Evaporation of the solvent under reduced pressure provided a MeOH extract (689.77 
g). A part of the MeOH extract (684.35 g) was partitioned same extraction protocol as described 
in Chapter 4.2.2. The following each soluble fractions were obtained: hexane (92.87 g), EtOAc 
(57.39 g), n-BuOH (72.06 g), and H2O (450.33 g). 
 
5.2.3. Preparation of sample solution 
For each sample, 5.0 mg of each sample (MeOH extract, hexane fraction, EtOAc fraction, 
BuOH fraction, and H2O fraction) was suspended in 1 mL of MeOH. The working solution at 
concentrations of 5.0 mg/mL (MeOH extract, BuOH fraction, and H2O fraction) and 0.5 mg/mL 
(hexane fraction, and EtOAc fraction) were used to determine the content of CL and DCL. Each 
supernatant was then filtered (Millex-LG 0.20 µm, 4 mm, Merck Ltd., MA, USA), and a 10 µL 
aliquot of each filtrate was analyzed by HPLC. 
 
5.2.4. Preparation of standard solution 
A stock standard solution was prepared by placing CL and DCL (each 1.00 mg) adding 1 
mL of MeOH. The solution contained CL and DCL at concentrations of each 1.00 mg/mL. The 
working solutions were used to construct calibration curves. (CL and DCL: 500 µg/mL, 100 
µg/mL, 50 µg/mL, 10 µg/mL, 5 µg/mL). Calibration curves were made by injecting a 10 µL 
aliquot of each working solution into the HPLC system.  
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5.2.5. HPLC instruments and conditions for CL and DCL 
The HPLC system was performed on a JASCO LC-2000 Plus series (JASCO, Tokyo, 
Japan) equipped with an intelligent UV-VIS detector (UV-2075 Plus), a quaternary gradient 
pump (PV-2089 Plus), an intelligent column oven (CO-2065 Plus), an intelligent autosampler 
(AS-2057 Plus), an interface (LC-Net II/ADC), and a data software (Chrom NAV). TSKgel 
ODS-100V column (4.6 × 250 mm, particle size 5 µm, Tosoh Corp. Tokyo, Japan) was used 
for the HPLC analysis at 40 ◦C with mobile phases acetonitrile and 0.1% aq. formic acid eluted 
according to the following gradient program: 0 min (40:60, v/v) → 20 min (100:0, v/v) → 30 
min (50:50, v/v, hold). The flow rate was 1 mL/min, the injection volume was 10.0 µL, and the 
detection wavelength was 225 nm. Peaks for CL and DCL were observed at 15.0 min, and 15.5 
min, respectively. 
 
5.2.6. Calibration 
Calibration curves were constructed with five standards prepared over the following 
concentration ranges: 5–500 µg/ml. Calibration curves were constructed by plotting 
concentration (µg/mL) on the horizontal axis and peak area (µV*sec) on the vertical axis. 
Linearity was determined using the correlation coefficient (r2). 
 
5.2.7. Materials for biological assays 
CL (purity > 95%) and DCL (purity > 98%) were purchased from Tokyo Chemical 
Industries (Tokyo, Japan). All other materials for biological assays using were the same as 
described in Chapter 3.2.1. 
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5.2.8. Cell culture and treatment 
See Chapter 2.2.3.  
 
5.2.9. Determination of cell proliferation 
See Chapter 4.2.6.  
 
5.2.10. Western blot analysis 
Cells (1 × 106 cells/dish) were plated on 6 cm dishes. After replacing with fresh medium, 
the cells were treated with hexane fraction or each compound for various time periods. All 
subsequent steps were performed same western blot analysis protocol as described in Chapter 
2.2.4. 
 
5.2.11. Statistical analysis 
See Chapter 2.2.6.  
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5.3. Results 
5.3.1. Comparison of antiproliferative effects of each fraction 
To identify the active compounds responsible for the antiproliferative effect, the crude 
extract was suspended in water and successively partitioned with the use of hexane, EtOAc, 
and n-BuOH. The cells were treated with 2.5, 5, 10, and 20 μg/mL of each fraction for 24 h, 
and cell proliferation was measured using MTT assay. As shown in Fig. 5.3, the hexane fraction 
most strongly suppressed the cell proliferation than the EtOAc, n-BuOH, and H2O fractions. 
 
 
 
 
 
Figure 5.3. Effects of fractions prepared from Mokko extract on cell proliferation. 
HepG2 cells were treated with each fraction prepared from the crude extract of Mokko at 
various concentrations for 24 h (A), and cells were treated with each fraction (B: 20 μg/mL) 
for the times indicated and cell proliferations were determined using MTT assay. The data 
are represented as the mean  S.D. of three individual experiments. ∗p < 0.05 compared with 
the control group. 
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5.3.2. Effect of hexane fraction on autophagosome formation and autophagy flux 
To confirm whether the hexane fraction inhibits autophagy, we investigated the effect of 
hexane fraction on the expression levels of both LC3-II and p62. The cells were treated with 
hexane fraction at 5 μg/mL for various time periods, and the levels of each protein were 
examined using western blotting. As shown in Fig. 5.4, the hexane fraction treatment clearly 
increased the levels of both LC3-II and p62. These results suggest that the hexane fraction 
deregulates the autophagic pathway by blocking autophagic flux, thereby resulting in the 
accumulation of p62 and LC3-II. 
 
 
 
 
 
 
 
Figure 5.4. Effect of hexane fraction on LC3-II and p62 expression levels. HepG2 cells 
were treated with hexane fraction prepared from the crude extract of Mokko at 5 μg/mL for 
the times indicated. The expression levels of LC3B, p62, and β-actin were determined by 
western blotting. The data shown are representative of three independent treatments using 
the same parameters with similar results. 
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5.3.3. TLC and HPLC analyses of CL, DCL, MeOH extract, and fractions 
Next, we confirmed the presence of major compounds in the hexane fraction. The 
confirmation test by TLC based on the Japanese Pharmacopoeia, and HPLC demonstrated that 
the hexane and EtOAc fractions mainly contained CL and DCL (Fig. 5.5 and 5.6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. TLC analysis of CL, DCL, MeOH extract, and fractions. TLC silica gel plate 
was visualized by spraying with 10% aq. sulfuric acid, which was followed by heating. 
Solvent; Hexane:Acetone = 7:3 
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5.3.4. Effects of CL and DCL on cell proliferation 
To investigate the effects of CL and DCL on the proliferation of the HepG2 cells, we 
treated the cells with 6.25, 12.5, 25, 50, and 100 μM of CL and DCL for 24 h in the MTT assay. 
As shown in Fig. 5.7, a significant decrease in cell proliferation was observed in the presence 
of CL or DCL. 
 
 
    Figure 5.6. HPLC chromatograms of CL, DCL, MeOH extract, and fractions.  
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5.3.5. Effects of CL and DCL on autophagosome formation and autophagy flux 
We next examined the effects of CL and DCL on the levels of both LC3-II and p62 to 
confirm autophagy. The cells were treated with the CL at 10 μM and with the DCL at 20 μM 
for various time periods. As shown in Fig. 5.8, the CL and DCL treatment clearly increased the 
levels of both LC3-II and p62. These results suggest that CL and DCL trigger autophagy 
inhibition by blocking the autophagic flux, thereby resulting in the accumulation of p62 and 
LC3-II. 
Figure 5.7. Effects of CL and DCL on cell proliferation. HepG2 cells were treated with 
CL and DCL at various concentrations for 24 h (A), and cells were treated with CL and DCL 
(100 µM) for the times indicated (B) and cell proliferations were determined using MTT 
assay. ETP was used as a model for inducing apoptotic cell death against HepG2 cells. The 
data are presented as the mean  S.D. of three individual experiments.p < 0.05 compared 
with the control group. 
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Figure 5.8. Effects of CL and DCL on LC3-II and p62 expression levels. HepG2 cells 
were treated with the indicated concentrations of CL and DCL for 24 h (A), or different 
durations (B). The expression levels of LC3B (A), p62 (B), and β-actin were determined by 
western blotting. BBR (50 M) is a positive control. The data shown are representative of 
three independent treatments using the same parameters with similar results. 
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5.3.6. Effects of CL and DCL on apoptosis-related proteins 
To determine whether the induction of apoptosis is associated with the antiproliferative 
effect of CL and DCL, we examined the effects of CL and DCL on caspase-3 and PARP. We 
used ETP as a positive control [20, 21]. As shown in Fig. 5.9, the CL and DCL weakly induced 
the activation of caspase-3 and PARP. These results suggest that the antiproliferative effect of 
CL and DCL might be partly caused by the induction of apoptosis. 
 
 
 
 
 
  
Figure 5.9. Effects of CL and DCL on the activation of caspase-3 and PARP cleavage. 
HepG2 cells were treated with indicated concentrations of CL and DCL for 12 or 24 h, 
respectively. The expression levels of caspase-3, PARP, and β-actin were determined by 
western blotting. ETP (100 M, 12 h) is a positive control. The data shown are representative 
of three independent treatments using the same parameters with similar results.  
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To determine whether autophagy is involved in the apoptosis-inducing activity of ETP, we 
investigated the effect of ETP on autophagy-related proteins. The cells were treated with ETP 
at 100 μM for various time periods. As shown in Fig. 5.10, ETP treatment clearly increased the 
LC3-II levels. However, ETP had no effect on p62 levels during treatment. These results suggest 
that ETP did not block autophagic flux. 
 
 
 
 
 
  
Figure 5.10. Effects of ETP on LC3-II and p62 expression levels. HepG2 cells were 
treated with ETP at 100 μM for the times indicated. The expression levels of LC3B, p62, 
and β-actin were determined by western blotting. The data shown are representative of three 
independent treatments using the same parameters with similar results. 
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5.4. Discussion 
As described in this chapter, we first determined the fraction of Mokko extract by using 
the antiproliferative activity as an index. Among the four fractions, the non-polar (hexane) to 
low-polar (EtOAc) fractions exerted strong antiproliferative activity, and the hexane fraction 
possessed the strongest antiproliferative activity (Fig. 5.3). Moreover, the hexane fraction 
showed autophagy inhibition by the accumulation of p62 and LC3-II (Fig. 5.4). Next, we 
confirmed the main compounds contained in the hexane fraction. TLC and HPLC analyses 
determined that the major compounds in the hexane and EtOAc fractions were CL and DCL 
(Fig. 5.5 and 5.6), which are widely known to be the primary active compounds in the Mokko 
extract [2]. Both CL and DCL exerted the antiproliferative activity (Fig. 5.7) and deregulated 
the autophagic pathway by blocking the autophagic flux, thereby resulting in the accumulation 
of p62 (Fig. 5.8). In HepG2 cells, CL and DCL weakly induced the activation of caspase-3 and 
the cleavage of PARP (Fig. 5.9), thereby suggesting that CL and DCL might be involved in the 
induction of apoptosis. Taken together, both CL and DCL might exert antiproliferative activity 
with the inhibition of autophagy and induction of apoptosis. Although ETP induced apoptosis, 
ETP did not block autophagic flux because p62 levels were not changed by ETP (Fig. 5.10). 
These findings imply that the mechanisms of actions of CL and DCL are different from that of 
ETP. Further investigations may provide new knowledge into the link between apoptosis and 
autophagy. 
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5.5. Conclusion 
In this chapter, we found that the non-polar (hexane) to low-polar (EtOAc) fractions of 
Mokko exerted exceedingly strong antiproliferative activity and inhibited autophagy on HepG2 
cells. TLC analysis confirmed that CL and DCL were primary sesquiterpene lactones contained 
in the hexane and EtOAc fractions and suppressed the proliferation of HepG2 cells. The 
analysis of autophagy-related proteins by using HepG2 cells demonstrated that CL and DCL 
might inhibit autophagy, thereby leading to the accumulation of p62. Interestingly, CL and DCL 
weakly evoked the activation of caspase-3 and the cleavage of PARP, thereby suggesting that 
the antiproliferative activity by CL and DCL are also partly involved in an apoptotic process.   
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Chapter 6 
Conclusions 
 
Autophagy is involved in cancer development [1–4]. This thesis focuses on the 
identification of natural products that suppress cancer cell proliferation and autophagy 
modulation. Autophagy is important for supporting tumor growth (see page 5, Chapter 1, Fig. 
1.2) [1–4]. The role of autophagy in cancer is complex because it depends on the organ, stage, 
and genetic context of the tumor. To develop future cancer therapy strategies, additional 
research is required to elucidate the role of autophagy in cancer. However, there are currently a 
few reports on compounds that modulate autophagy. For potential clinical applications, the 
identification of compounds that induce or inhibit autophagy is valuable [1, 2, 5–12]. 
Autophagy inducers may provide beneficial therapeutic effects in certain neurodegeneration, 
infection, and cytoprotection [5, 6, 11], whereas autophagy inhibitors have been suggested to 
be beneficial agents for cancer therapy [1, 2, 4–12]. Autophagy inhibitors can be classified 
according to whether their inhibitory step occurs before or after autophagosome formation. 
Many current clinical trials have shown that inhibitors of late-stage autophagy can be used in 
combination with existing anticancer drugs to overcome resistance and that this combination is 
very beneficial (see page 8, Chapter 1, Table 1.1) [4, 11, 12]. Moreover, both late- and early-
stage interventions are required to achieve a more efficient inhibition of autophagy in order to 
establish a broader and more flexible cancer therapy strategy. Recent studies have shown that 
natural products have beneficial effects on cancer therapy by inhibiting autophagy [13-17]. 
These results suggest that identification of autophagy modulators from natural products that 
both induce and inhibit autophagy is important for cancer therapy.  
The primary goal of this thesis was to discover crude extracts that suppress both cancer 
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proliferation and autophagy. In Chapter 2, we screened 130 kinds of crude drugs by western 
blotting to monitor LC3-II levels. Some research used ELISA to observe LC3 because the 
method of ELISA is simple and rapid. However, it is difficult to distinguish between LC3-I and 
–II by ELISA. On the other hand, western blotting can determine the precise effects of 
compounds on LC3-II. Thus, we employed the western blotting. We found that 24 crude extracts 
increased the levels of LC3-II. Crude extracts prepared from Goboshi (burdock fruit), Soboku 
(sappan wood), Mokko (saussurea root), Rengyo (forsythia fruit), and Hikai (dioscorea) 
significantly suppressed the proliferation of HepG2 cells and increased the levels of p62, 
suggesting that these crude extracts inhibited autophagy. In contrast, crude extracts prepared 
from Hishinomi (water chestnut), Biwayo (loquat leaf), and Binroji (areca) induced cell growth 
and decreased or did not affect the levels of p62. These results suggested that these crude 
extracts induced autophagy contributing to cell growth (Fig. 6.1). These results further indicate 
that the compounds contained in these crude extracts may modulate cell proliferation and 
autophagy in HepG2 cells. Simultaneously, these active compounds may lead to the 
development of new anticancer drugs as autophagy modulators and to provide new reagents for 
autophagy research. 
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The second goal of this thesis was to identify the major active compounds that suppress 
autophagy and cell proliferation from the crude extracts and to elucidate their molecular 
mechanisms of autophagy inhibition. 3-MA and CQ have been reported to suppress autophagy 
and cell proliferation in HepG2 cells [18, 19]. In addition, HCQ, an analog of CQ, is used for 
clinical trials to develop anticancer drug (see page 7, chapter 1) [4, 11, 12] . Therefore, this 
thesis focused on identifying compounds suppress autophagy and cell proliferation, like 3-MA 
and CQ.  
In Chapter 3, we demonstrated the effects of ARG, a bioactive lignan contained in both 
Goboshi and Rengyo extracts, on cell proliferation and autophagy-related proteins. ARG 
suppressed the proliferation of HepG2 cells. Analysis of autophagy-related proteins in HepG2 
and MCF-7 cells demonstrated that ARG suppressed autophagy leading to the accumulation of 
Figure 6.1. Schematic illustrating the results of screening using crude extract library. 
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p62. The stages of autophagy suppressed by ARG differed from those by 3-MA or CQ. Further, 
ARG suppressed starvation-induced autophagy. In contrast, ARG did not affect caspase-3 
activation and PARP cleavage, suggesting that the antiproliferative activity of ARG was 
independent of caspase-3-mediated apoptosis. Taken together, we conclude that ARG 
suppressed cell proliferation and autophagy. 
In Chapter 4, we demonstrated that the medium-polar (n-BuOH) to high-polar (H2O) 
fractions of Hikai exerted strong antiproliferative activity and inhibition of autophagy on 
HepG2 cells. Phytochemical investigations of the most active n-BuOH fraction achieved the 
isolation of two spirostan-type steroidal saponins, dioscin (DC, 1), yamogenin 3-O--L- 
rhamnopyranosyl (1→4)-O--L-rhamnopyranosyl(1→2)--D-glucopyranoside (YG, 2), and a 
frostane-type steroidal saponins, protodioscin (PDC, 3). Further, acid hydrolysis of 1 and 2 
produced the aglycones diosgenin (4) and yamogenin (5), respectively. Compounds 1–5 all 
suppressed the proliferation of HepG2 cells. The analysis of structure-activity relationships 
indicated that the 25(R)-conformation, structures with a sugar moiety, and the spirostan-type 
aglycone moiety contributed to antiproliferative activity. Analysis of autophagy-related 
proteins demonstrated that 1–3 inhibited autophagy. In contrast, 1–3 did not significantly affect 
caspase-3 activation and PARP cleavage, suggesting that the antiproliferative activity of 1–3 
occurred independently of caspase-3-mediated apoptosis. We conclude therefore that 1–3, the 
active compounds from Hikai extracts, suppressed cell proliferation and autophagy. 
In Chapter 5, we demonstrated that the non-polar (hexane) to low-polar (EtOAc) fractions 
of Mokko exerted strong antiproliferative activity and inhibition of autophagy in HepG2 cells. 
TLC and HPLC analyses showed CL and DCL were major sesquiterpene lactones contained in 
the hexane and EtOAc fractions. CL and DCL suppressed the proliferation of HepG2 cells. 
Analysis of autophagy-related proteins demonstrated that CL and DCL inhibited autophagy. 
Moreover, CL and DCL weakly activated caspase-3 and cleaved PARP, suggesting that the 
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antiproliferative activity of CL and DCL were involved in apoptosis. We conclude that CL and 
DCL suppress cell proliferation and autophagy, and also induce apoptosis. 
In summary, this thesis reports the discovery of six autophagy-inhibiting compounds 
(Table 6.1) that suppressed cell proliferation of HepG2 cells. However, each compound had 
different characteristics in terms of the stages of autophagy inhibition and the involvement of 
apoptosis (Fig. 6.2). 
 
 
Table 6.1. List of autophagy-inhibiting compounds identified in this thesis. 
Compound name 
Content 
crude drug 
IC50 
（µM） 
Chapter 
ARG Arctigenin 
Goboshi 
Rengyo 
> 100 3 
DC Dioscin Hikai 4.09 4 
YG 
Yamogenin 3-O--L-rhamnopyranosyl 
(1→4)-O--L-rhamnopyranosyl 
(1→2) --D-glucopyranoside 
Hikai 15.63 4 
PDC Protodioscin Hikai 34.51 4 
CL Costunolide Mokko 70.68 5 
DCL Dehydrocostuslactone Mokko 25.36 5 
 The IC50 value of each compound at 24 h treatments on cell proliferation. 
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ARG in both Goboshi and Rengyo extracts inhibited the early-stage of autophagy. In 
contrast, the other five compounds inhibited the late-stage of autophagy. DC (1) and YG (2) in 
Hikai extract strongly suppressed cell proliferation. DC (1) and YG (2) were not involved in 
apoptosis-related proteins, suggesting that antiproliferative activity of DC (1) and YG (2) 
occurred independently of caspase-3-mediated apoptosis. In addition, although PDC (3) also 
inhibited the late-stage of autophagy, its antiproliferative activity was weaker than that of DC 
Figure 6.2. Summary of autophagy-inhibiting compounds identified in this thesis. 
The antiproliferative efficacy of each compound was compared based on IC50 values at 
24 h treatments. 
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(1) and YG (2). Moreover, CL and DCL in Mokko extract triggered the activation of apoptosis-
related proteins suggested that CL and DCL have dual functions of autophagy inhibition and 
apoptosis induction.  
The screening protocol used in this thesis is not suitable for identifying crude extracts that 
inhibit the early-stage of autophagy. In fact, five crude extracts selected for screening increased 
the levels of both LC3-II and p62, which are characteristics of late-stage inhibition of autophagy. 
Nevertheless, based on the results presented in Chapter 3, we concluded that ARG inhibits the 
early-stage of autophagy. Thus, this screening method may have some flexibility. This 
flexibility is particularly useful in research fields with many unclear points such as the study of 
autophagic activity.  
In Chapter 3, we demonstrated that ARG suppressed cell proliferation and autophagy in 
HepG2 cells. Suresh et al. screened 500 medicinal plant extracts used in Kampo medicines. 
They found that a CH2Cl2-soluble extract of Goboshi preferentially suppresses the survival rate 
of cancer cells under nutritional deficiency. In addition, they reported that ARG isolated from 
the Goboshi extract strongly suppresses the growth of several pancreatic cancer cell lines [20]. 
In Japan, ARG has already been developed as investigational drug GBS-01, which is an ARG-
rich Goboshi extract containing ≥ 3% ARG. A phase I/II study of GBS-01 has been performed 
in patients with gemcitabine-refractory advanced pancreatic cancer. The clinical safety and 
potential benefits of GBS-01 monotherapy were confirmed in patients with advanced pancreatic 
cancer refractory to gemcitabine therapy [21, 22]. The detailed method for the preparation of 
GBS-01 is reported in patent document JP-4963738-B2. These data strongly support our results 
showing that ARG has potential applications in the development of anticancer agents.  
Ongoing clinical trials for cancer therapy are assessing the safety and efficacy of CQ and 
HCQ, which inhibit the late-stage autophagy [11]. In this thesis, DC (1), YG (2), PDC (3), CL, 
and DCL inhibit the late-stage of autophagy. The chemical structures of these compounds differ 
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from existing those of drugs used as inhibitors of autophagy, which may lead to the development 
of new autophagy inhibitor. Although HepG2 cells have been reported to be resistant to 
apoptosis [23], CL and DCL inhibited autophagy and induced apoptosis in HepG2 cells. There 
are few reports on such compounds having both activities. Thus, further research is required to 
determine the functions of CL and DCL using different cancer cell lines. 
In this thesis, we focused on the effects of each compound on autophagy, cell proliferation, 
and apoptosis. Although it is known that autophagy is related with cell cycle, we could not 
determine the effects of each compound on cell cycle [24, 25]. Future studies are needed to 
elucidate the cell cycle. 
In conclusion, autophagy-inhibiting compounds found in this thesis may contribute to the 
development of new anticancer drugs and serve as new analytical tools for autophagy research. 
We hope that the research approach described in this thesis, which screened for potential drugs 
focusing on crude drugs, will contribute to the discovery of new and improved therapies for 
diverse diseases.   
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